LDCT screening shifts SCLC to earlier stages, improves survival

Low-dose CT lung cancer screening is associated with earlier detection of small cell lung cancer and significantly improved overall survival, with screened patients showing 28% three-year survival compared to 10.8% in unscreened patients, according to recent research published in JAMA Oncology.

  • LDCT screening detected SCLC at stage I in 15.2% of screened patients versus only 4.4% of unscreened patients
  • Screened patients had 44.2% distant disease compared to 70.4% in unscreened groups
  • Three-year overall survival was 28% for screened patients versus 10.8% for unscreened patients
  • Study analyzed 17,099 Medicare beneficiaries aged 65-78 diagnosed with SCLC between 2015-2021
  • Only 5.5% of patients had undergone LDCT screening in the 12 months before diagnosis

Low-dose CT (LDCT) lung cancer screening is associated with earlier detection of small cell lung cancer (SCLC) and improved overall survival among diagnosed patients, according to research published November 19 in JAMA Oncology. 

A group from Mass General Brigham examined outcomes among Medicare beneficiaries with SCLC who did or did not undergo LDCT screening before diagnosis, with findings suggesting a meaningful stage shift and survival benefit for this aggressive, fast-growing cancer, noted lead author Alexandra Potter, of Mass General Brigham in Boston, and colleagues. 

"This contrasts the findings of most prior studies published on this topic to date," the researchers noted. 

Prior evidence on LDCT screening and SCLC outcomes have consisted largely of small, older studies, the authors wrote. Of seven studies evaluating SCLC outcomes in patients who underwent lung cancer screening, six concluded LDCT does not improve SCLC outcomes, but those studies included as few as 10 patients, they added. In addition, most were conducted in the 1990s and early 2000s, before advancements in LDCT technology that have since improved early-stage lung cancer detection, the group noted. 

To assess whether LDCT screening is associated with stage shift and improved survival under current practices, the researchers conducted a retrospective analysis of linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data including 17,099 patients aged 65 to 78 years old diagnosed with SCLC between 2015 and 2021. Of these, 949 (5.5%) had undergone at least one LDCT scan in the 12 months before diagnosis and 16,150 (94.5%) had not. 

According to the analysis, screened patients were significantly less likely to present with distant disease than unscreened patients (44.2% versus 70.4%) and more likely to be diagnosed at stage I (15.2% versus 4.4%). Three-year overall survival was 28% in the screened group versus 10.8% in the unscreened group. Both findings were consistent in propensity score–matched analysis, the researchers reported. 

"Results suggest that lung cancer screening was associated with earlier detection of SCLC and improved overall survival among patients diagnosed with SCLC," the group wrote. 

As LDCT screening adoption grows, more SCLC cases may be detected at earlier stages, the researchers suggested. The findings point to a need for screening programs to develop systems-based pathways for rapid early-stage SCLC management to maximize survival gains from earlier detection, they wrote. Prospective data will be needed to confirm whether the association translates into a mortality benefit at the population level, the researchers added. 

"Our findings support an association between LDCT screening and a beneficial SCLC stage shift and improved survival but do not establish causality," the group concluded. 

The full study is available here.

Page 1 of 696
Next Page